EVEREST MED.LTD DL-0001 (6HN) - Total Assets
Based on the latest financial reports, EVEREST MED.LTD DL-0001 (6HN) holds total assets worth €6.83 Billion EUR (≈ $7.99 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 6HN total equity for net asset value and shareholders' equity analysis.
EVEREST MED.LTD DL-0001 - Total Assets Trend (2021–2025)
This chart illustrates how EVEREST MED.LTD DL-0001's total assets have evolved over time, based on quarterly financial data. Check EVEREST MED.LTD DL-0001 (6HN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
EVEREST MED.LTD DL-0001 - Asset Composition Analysis
Current Asset Composition (December 2025)
EVEREST MED.LTD DL-0001's total assets of €6.83 Billion consist of 49.4% current assets and 50.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.0% |
| Accounts Receivable | €500.02 Million | 7.3% |
| Inventory | €32.22 Million | 0.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.12 Billion | 31.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how EVEREST MED.LTD DL-0001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is EVEREST MED.LTD DL-0001 worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EVEREST MED.LTD DL-0001's current assets represent 49.4% of total assets in 2025, an increase from 40.5% in 2021.
- Cash Position: Cash and equivalents constituted 27.0% of total assets in 2025, down from 39.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, a decrease from 42.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.
EVEREST MED.LTD DL-0001 Competitors by Total Assets
Key competitors of EVEREST MED.LTD DL-0001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
EVEREST MED.LTD DL-0001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.89 | 2.54 | 4.68 |
| Quick Ratio | 4.85 | 2.52 | 4.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.68 Billion | €1.22 Billion | €1.77 Billion |
EVEREST MED.LTD DL-0001 - Advanced Valuation Insights
This section examines the relationship between EVEREST MED.LTD DL-0001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 37.8% |
| Total Assets | €6.83 Billion |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values EVEREST MED.LTD DL-0001's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: EVEREST MED.LTD DL-0001's assets grew by 37.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for EVEREST MED.LTD DL-0001 (2021–2025)
The table below shows the annual total assets of EVEREST MED.LTD DL-0001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €6.83 Billion ≈ $7.99 Billion |
+37.83% |
| 2024-12-31 | €4.96 Billion ≈ $5.80 Billion |
-14.10% |
| 2023-12-31 | €5.77 Billion ≈ $6.75 Billion |
-12.73% |
| 2022-12-31 | €6.61 Billion ≈ $7.73 Billion |
-0.47% |
| 2021-12-31 | €6.65 Billion ≈ $7.77 Billion |
-- |
About EVEREST MED.LTD DL-0001
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocyc… Read more